Cell Viability Assays Market - Forecast(2024 - 2030)

Cell Viability Assays Market Overview

Cell Viability Assays Market size is forecast to reach US$2.8 billion by 2030, after growing at a CAGR of 8.6% during 2024-2030. Cell viability assays are tests used to determine the health and survival of cells in response to various treatments or conditions. These assays are crucial for assessing the effectiveness of drugs, understanding disease mechanisms and developing new therapies. The market for cell viability assays is growing due to the rising prevalence of chronic diseases like cancer and diabetes. These diseases increase the need for reliable methods to monitor and evaluate treatments. Moreover, advancements in biotechnology and substantial research and development investments by pharmaceutical companies are improving the precision and efficiency of these testing methods. Together, these factors are driving the growth and development of the cell viability assays market, helping it expand in both medical and research fields. In addition to these factors, the increasing demand for regenerative medicine and stem cell research is also contributing to the market's growth, as these fields rely heavily on accurate cell viability testing for developing therapies and understanding cell behavior. Furthermore, emerging technologies like CRISPR and next-generation sequencing (NGS) are enabling more customized assays, adapting to the needs of patient-centered approaches. These combined factors are propelling the expansion of the cell viability assays market across both medical and research fields.

Two primary factors significantly influence the cell viability assays market. Firstly, the increasing use of High-Throughput Screening (HTS) in drug discovery is driving market growth. Pharmaceutical companies are increasingly using HTS to quickly test large numbers of potential drug compounds. For example, Northwestern University's High Throughput Analysis Laboratory uses advanced technology to speed up drug discovery processes. Secondly, the growing focus on personalized medicine is creating demand for accurate and patient-specific viability assays. Tailoring treatments to individual genetic makeup requires precise measurements of cell health. Research from Stanford Medicine emphasizes the importance of personalized approaches for better treatment outcomes and fewer side effects. 

Market Snapshot: 

Report Coverage

The report "Cell Viability Assays Market Report – Forecast (2024-2030)" by IndustryARC covers an in-depth analysis of the following segments of the Cell Viability Assays market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

1. The COVID-19 pandemic severely disrupted the cell viability assay market, leading to shortages of key reagents like enzymes and buffers, primarily sourced from China and India. Many R&D projects were delayed as resources were redirected to COVID-19 research, decreasing demand for assays in areas like cancer research. However, cell viability assays were crucial in developing COVID-19 vaccines, helping assess the safety and effectiveness of vaccine candidates during preclinical stages.
2. The Russian invasion of Ukraine has worsened supply chain issues in the cell viability assay market. Additionally, rising energy prices in Europe have increased manufacturing and transportation costs, contributing to inflation and higher prices for assay kits and reagents.

Key Takeaways

Cell Viability Assays Kits and Reagents are the Largest Segment

Reagents and assay kits represent the largest segment in the Cell Viability Assays Market driven by their widespread use in various research and clinical applications. Tetrazolium Reduction Assays, including MTT, XTT and WST are the most commonly used assay types in the Cell Viability Assays Market due to their reliability and effectiveness in measuring cellular metabolic activity. These assays are favored for their ability to provide consistent and reproducible results, particularly in assessing cell proliferation and cytotoxicity. According to a journal on PLOS, these assays are widely used because they can be easily adapted to various experimental conditions and cell types, providing a reliable method for evaluating cell viability. Additionally, the formazan crystals produced by these assays can be quantitatively measured, offering a clear and direct indication of cellular health and metabolic activity. This versatility and reliability make Tetrazolium Reduction Assays a cornerstone in cell viability studies across different research fields.

Drug Discovery & Development is the Largest Application

The Drug Discovery and Development segment is the largest in the Cell Viability Assays Market due to the critical role these assays play in evaluating potential drug candidates. Cell viability assays are integral in assessing the effects of new compounds on living cells, helping researchers determine the safety and efficacy of drugs at various stages of development. According to data from the National Institutes of Health (NIH), the process of developing a new medicine, from target identification to market approval, can take over 12 years and cost approximately $2.6 billion. These assays can make the process faster by allowing researchers to quickly screen large numbers of potential drugs, identifying and discarding ineffective or toxic compounds early on. This streamlines the drug development pipeline, ensuring that only the most promising candidates advance, thereby accelerating the overall process and reducing the time and resources required to bring new therapies to market.

North America Dominates the Market

North America is leading the Cell Viability Assays Market, driven by advanced healthcare infrastructure, significant R&D investments and a high prevalence of chronic diseases like cancer. The region’s robust healthcare system including cutting-edge research facilities and a strong biopharmaceutical sector is bolstered by substantial government funding. In the United States, agencies such as the National Institutes of Health (NIH) and its National Cancer Institute (NCI) play a crucial role. The NCI's allocation of $7.8 billion part of a $48.6 billion NIH budget supports innovative clinical trials and cancer research at its designated Cancer Centers. This funding ensures continuous progress in cell-based therapeutics, essential for treating complex diseases. Additionally, North America hosts numerous leading pharmaceutical and biotech companies, heavily investing in R&D, which further propels the adoption of advanced cell viability assays. As per the American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths occured in the United States, highlighting the urgent need for these assays in diagnostics and therapeutics. Consequently, North America's comprehensive healthcare infrastructure, combined with its research capabilities and biopharmaceutical strength, solidifies its dominance in the Cell Viability Assays Market.

Rising Prevalence of Chronic Diseases Drives the Market

The increasing prevalence of chronic diseases such as cancer and diabetes are significantly driving demand in the Cell Viability Market, as these conditions require effective treatment monitoring methods. According to the World Health Organization (WHO), 2022 saw an estimated 20 million new cancer cases globally, resulting in 9.7 million deaths, with 53.5 million people living within five years of a cancer diagnosis and states that over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Additionally, the number of people with diabetes is projected to increase to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation (IDF). Cell viability assays are critical in this context, as they help evaluate the effectiveness of treatments by measuring cell health and survival post-therapy. In cancer treatment, these assays are used to determine how many cancer cells remain viable after interventions, guiding necessary adjustments. In diabetes management, they help monitor cellular responses to medications.

Advancements in Biotech and R&D to Boost Market Growth

Advancements in biotechnology coupled with significant research and development investments by pharmaceutical companies are crucial drivers in the Cell Viability Assays Market enhancing the precision and efficiency of testing methods. Accurately assessing cell viability in vitro is critical, particularly in drug discovery, where toxicity is a leading cause of candidate failure. Current estimates indicate that the 10- to 14-year discovery and development cycle for one new FDA-approved drug costs over $2 billion, factoring in that about 90 percent of products in development fail. The integration of high-content, multiplexed assays, which assess multiple markers simultaneously, offers a more comprehensive and accurate prediction of a drug's cytotoxicity. This approach significantly reduces late-stage failures in clinical trials, protecting substantial financial investments by pharmaceutical companies and enhancing the efficiency of the overall drug discovery process. In light of these challenges, Drug Discovery and Development reports that pharma giants are investing heavily in R&D, with most firms dedicating between 14% and 30% of their revenues to research and development efforts, aiming to mitigate the high risks associated with drug discovery and development.

False Positives in Cell Viability Assays to Hamper Growth

The reliance on the MTT assay in the cell viability assays market poses a significant challenge due to its susceptibility to false-positive results particularly when testing plant extracts. As demonstrated by research conducted by the National Institute of Health (NIH), the MTT assay can overestimate cell viability and underestimate cytotoxicity especially when extracts interfere with the assay compound, leading to misleading conclusions. This issue is critical as accurate viability assessments are essential for drug development and toxicity testing. The ATP assay, by contrast, provides more reliable results as confirmed by microscopy and fluorescence imaging which align with observed cell death. The variability in IC50 values between the MTT and ATP assays further underscores the need for careful selection and interpretation of viability assays.

For more details on this report - Request for Sample

Cell Viability Assays Industry Outlook

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the Cell Viability Assays market. Global Cell Viability Assays top 10 companies include:
1.    Thermo Fisher Scientific
2.    Merck Group
3.    Promega Corporation
4.    Bio-Rad Laboratories
5.    Abcam
6.    Agilent Technologies
7.    BD Biosciences
8.    PerkinElmer
9.    Danaher Corporation
10.    Enzo Life Sciences

Scope of the Report: 

For more Lifesciences and Healthcare related reports, please click here